title: Broad-spectrum β-lactam antibiotics for treating experimental peritonitis in mice due to Klebsiella pneumoniae producing the carbapenemase OXA-48.
abstract: A lethal peritonitis model was induced in mice with a Klebsiella pneumoniae isolate producing the carbapenemase OXA-48. Administration of a single dose (up to 100 mg/kg) of the antibiotic piperacillin-tazobactam, imipenem-cilastatin, ertapenem, or cefotaxime had little or no impact on lethality. Ceftazidime had the highest efficacy in vivo, which mirrored its in vitro activity; this was not the case for carbapenems. Therefore, ceftazidime may be recommended for the treatment of infections due to OXA-48 producers if they do not coproduce an extended-spectrum β-lactamase or a plasmid-mediated AmpC cephalosporinase.
authors.affiliation: INSERM ERI 23 Pharmacology of Antimicrobial Agents, Centre Hospitalier Universitaire de Poitiers, and Université de Poitiers, Poitiers, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Mimoz
authors.forename: Nicolas
authors.initials: N
authors.lastname: Grégoire
authors.forename: Laurent
authors.initials: L
authors.lastname: Poirel
authors.forename: Manuella
authors.initials: M
authors.lastname: Marliat
authors.forename: William
authors.initials: W
authors.lastname: Couet
authors.forename: Patrice
authors.initials: P
authors.lastname: Nordmann
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000235:genetics*; D002439:Cefotaxime / Q000008:administration & dosage / Q000627:therapeutic use; D002442:Ceftazidime / Q000008:administration & dosage / Q000627:therapeutic use; D015377:Cilastatin / Q000008:administration & dosage / Q000627:therapeutic use; D000077728:Cilastatin, Imipenem Drug Combination; D004338:Drug Combinations; D000077727:Ertapenem; D015378:Imipenem / Q000008:administration & dosage / Q000627:therapeutic use; D007710:Klebsiella Infections / Q000188:drug therapy* / Q000382:microbiology; D007711:Klebsiella pneumoniae / Q000235:genetics* / Q000378:metabolism / Q000472:pathogenicity; D007928:Lethal Dose 50; D051379:Mice; D010397:Penicillanic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D010538:Peritonitis / Q000188:drug therapy* / Q000382:microbiology; D010878:Piperacillin / Q000008:administration & dosage / Q000627:therapeutic use; D000077725:Piperacillin, Tazobactam Drug Combination; D010957:Plasmids / Q000235:genetics; D015996:Survival Rate; D018440:beta-Lactam Resistance / Q000235:genetics; D001618:beta-Lactamases / Q000235:genetics*; D047090:beta-Lactams / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D004338:Drug Combinations; D047090:beta-Lactams; D015377:Cilastatin; D000077725:Piperacillin, Tazobactam Drug Combination; D015378:Imipenem; D010397:Penicillanic Acid; D000077728:Cilastatin, Imipenem Drug Combination; D002442:Ceftazidime; C048795:AmpC beta-lactamases; D001618:beta-Lactamases; C108449:oxacillinase; D000077727:Ertapenem; D002439:Cefotaxime; D010878:Piperacillin